amring-partner-altacor

Search for:

Nordic Group B.V. Through its Subsidiary Nordic Pharma, Inc. (U.S.), Announces LACRIFILL® Canalicular Gel Inclusion in New Dry Eye Workshop (DEWS) III Management and Therapy Report From The Tear Film and Ocular Surface Society (TFOS) in American Journal of Ophthalmology
Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., announces launch of authorized generic of Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension)
Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Presenting Patient Data and Patient Experience Study for LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, at the American Society of Cataract and Refractive Surgery Annual Meeting
Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Announces Details of LACRIFILL® Canalicular Gel Poster Presentation At SECO 2025
Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Continues Its Introduction of LACRIFILL^® Canalicular Gel, a Novel Therapy for Dry Eye, During American Academy of Ophthalmology (AAO) 2024